Aclaris Therapeutics (ACRS) announced the availability of a new publication describing properties of Aclaris Therapeutics’ ATI-2138, a novel investigational covalent inhibitor of interleukin-2 ...

Aclaris Therapeutics stock opened at $2.39 on Friday. The stock has a market capitalization of $170.72 million, a PE ratio of -4.60 and a beta of 0.50. The business has a 50 day simple moving ...

Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. The company’s lead asset, ATI-045, shows promising phase 2a results in atopic ...

WAYNE, Pa. - Aclaris Therapeutics, Inc. (NASDAQ: NASDAQ:ACRS), a clinical-stage biopharmaceutical company with a market capitalization of $255 million specializing in the development of treatments ...

In Quezon City, the company replaced old pipes at DMA Rosalia with 409 linear meters of 75-millimeter (mm) to 100-mm newer and more resilient ones to further improve water service to Barangay ...

WAYNE, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno ...

Aclaris reports potential of ATI-2138 as a dual inhibitor for inflammatory diseases, with promising preclinical and clinical trial results. Aclaris Therapeutics, Inc. has announced the publication ...

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has been assigned an average recommendation of “Buy” from the seven research firms that are covering the stock, MarketBeat reports.

Bill Sullivan receives funding from the National Institutes of Health. Water that comes straight from natural sources, dubbed “raw water,” is gaining popularity. Raw water advocates reject ...

WAYNE, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for ...

WAYNE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno ...